ABSTRACT
The assessment of response to therapy in glioblastoma remains a challenge, because the surrogate measures of survival are subject to radiographic misinterpretation. A solid and reliable definition of progression is needed for both clinical decision-making and for evaluating response within the clinical trials. Historically, assessment criteria have used radiologic and clinical features aimed to correctly classify patients into progressive or non-progressive disease. The widely used RANO criteria are a valuable tool in disease evaluation, both in the clinical setting and in the clinical trials. However, assessment criteria have certain limitations that emerging image techniques have tried to overcome. Differentiating true progression from treatment-related changes (like pseudoprogression or pseudoresponse) is crucial in order not to prematurely discontinue adjuvant chemotherapy or redirect the patient to second-line options. This fact underscores the need for advanced radiologic techniques, like specific diffusion and perfusion MRI sequences, MR spectroscopy and PET, which seem to play a role in distinguishing these phenomena
No disponible
Subject(s)
Humans , Glioblastoma/pathology , Brain Neoplasms/pathology , Glioblastoma/therapy , Brain Neoplasms/therapy , Necrosis/etiology , Disease Progression , Treatment OutcomeABSTRACT
The assessment of response to therapy in glioblastoma remains a challenge, because the surrogate measures of survival are subject to radiographic misinterpretation. A solid and reliable definition of progression is needed for both clinical decision-making and for evaluating response within the clinical trials. Historically, assessment criteria have used radiologic and clinical features aimed to correctly classify patients into progressive or non-progressive disease. The widely used RANO criteria are a valuable tool in disease evaluation, both in the clinical setting and in the clinical trials. However, assessment criteria have certain limitations that emerging image techniques have tried to overcome. Differentiating true progression from treatment-related changes (like pseudoprogression or pseudoresponse) is crucial in order not to prematurely discontinue adjuvant chemotherapy or redirect the patient to second-line options. This fact underscores the need for advanced radiologic techniques, like specific diffusion and perfusion MRI sequences, MR spectroscopy and PET, which seem to play a role in distinguishing these phenomena.
Subject(s)
Brain Neoplasms/pathology , Diagnostic Imaging/methods , Glioblastoma/pathology , Radiation Injuries/pathology , Response Evaluation Criteria in Solid Tumors , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/therapy , Disease Progression , Glioblastoma/diagnostic imaging , Glioblastoma/therapy , Humans , Radiation Injuries/diagnostic imaging , Treatment OutcomeABSTRACT
Objetivos: Validar una técnica de cribaje para la valoración del traumatismo craneoencefálico(TCE) leve con respecto a un patrón-oro de neuroimagen, para confirmar el papel de la proteína (..) (AU)
Objectives: To validate testing for (..) (AU)
Subject(s)
Humans , S100 Proteins/analysis , Craniocerebral Trauma/diagnosis , Hospitalization/statistics & numerical data , Tomography, X-Ray Computed , Glasgow Outcome ScaleABSTRACT
Presentarnos un caso de neumonía por Mycoplasma pneumoniae en un paciente de seis años de edad. La sospecha diagnóstica se basó en la clínica y en las pruebas de imagen, confirmándose posteriormente con la serología. El propósito de este artículo es destacar que, dentro de la variabilidad de presentación radiológica de la neumonía por micoplasma, existe un patrón radiológico característico que debe orientar el diagnóstico hacia dicha entidad (AU)
Subject(s)
Child , Humans , Mycoplasma pneumoniae , Pneumonia, Mycoplasma/microbiology , Pneumonia, Mycoplasma , Pneumonia, Mycoplasma/drug therapy , Erythromycin/therapeutic use , Lung Diseases, Interstitial , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/microbiologyABSTRACT
No disponible
